why choose us

First received: October 23, 2023

Clinical Trial: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Study Status: Completed

Recruit Status: RECRUITING

Condition: Systemic Lupus Erythematosus

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus

Brief Summary: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Systemic Lupus Erythematosus

Read more